Peer-Reviewed Journal Details
Mandatory Fields
Eary, JF,O'Sullivan, F,Powitan, Y,Chandhury, KR,Vernon, C,Bruckner, JD,Conrad, EU;
2002
February
Journal of Nuclear Medicine
Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis
Validated
()
Optional Fields
sarcoma FDG PET SUVmax disease-free interval survival POSITRON-EMISSION-TOMOGRAPHY SOFT-TISSUE SARCOMA MUSCULOSKELETAL TUMORS BONE
29
1149
1154
In a retrospective analysis of patients with sarcoma who underwent fluorodeoxyglucose positron emission tomography (FDG PET) imaging, tumor maximum FDG uptake was analyzed for ability to predict patient survival and disease-free interval. Two hundred and nine patients with sarcoma were imaged prior to treatment with neoadjuvant chemotherapy or resection. Tumor FDG uptake expressed as maximum standard uptake value (SUVmax) was compared with disease-free and overall survival. A multivariate Cox regression analysis was applied to examine the role of SUVmax in predicting time to death or disease progression, after adjusting for standard clinical prognostic factors. The multivariate analyses showed that the SUVmax information is a statistically significant independent predictor of patient survival. Tumors with larger SUVmax have a significantly poorer prognosis. This retrospective analysis indicates that the sarcoma tumor SUVmax value determined by PET is an independent predictor of survival and disease progression.
DOI 10.1007/s00259-002-0859-5
Grant Details